These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37043935)

  • 21. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake?
    Policarpo S; Carvalhana S; Craciun A; Crespo RR; Cortez-Pinto H
    Nutrients; 2022 Mar; 14(7):. PubMed ID: 35405948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAFLD and MAFLD as emerging causes of HCC: A populational study.
    Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
    JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease.
    Liu J; Lv H; Wang J; Zhu Q; Chen G; Jiang Y; Zhao K; Shao L; Shi J; Pan X
    Ann Hepatol; 2023; 28(2):100892. PubMed ID: 36577468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    Guo B; Guo Y; Nima Q; Feng Y; Wang Z; Lu R; Baimayangji ; Ma Y; Zhou J; Xu H; Chen L; Chen G; Li S; Tong H; Ding X; Zhao X;
    J Hepatol; 2022 Mar; 76(3):518-525. PubMed ID: 34883157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
    Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
    Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
    Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Observational and Cross-Sectional Study of the Prevalence of Breast Lesions and Metabolic Dysfunction-Associated Fatty Liver Disease and their Relationship in China.
    Li S; Xu Z; Li H; Tang J; Liang XY; Tian S; Wu J; Li X; Liu ZL; Xiao J; Chen YL; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    J Gastrointestin Liver Dis; 2022 Mar; 31(1):31-39. PubMed ID: 35306559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.
    Fan H; Li L; Liu Z; Zhang P; Wu S; Han X; Chen X; Suo C; Cao L; Zhang T
    BMC Gastroenterol; 2023 Jan; 23(1):3. PubMed ID: 36604612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study.
    Okamoto M; Miyake T; Kitai K; Furukawa S; Yamamoto S; Senba H; Kanzaki S; Deguchi A; Koizumi M; Ishihara T; Miyaoka H; Yoshida O; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    PLoS One; 2018; 13(4):e0195147. PubMed ID: 29664906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis.
    Rodríguez-Antonio I; López-Sánchez GN; Reyes-Gómez VA; Contreras-Flores EH; Farías-García F; Espejel-Deloiza M; Durán-Padilla MA; Chablé-Montero F; Uribe M; Chávez-Tapia NC; Montalvo-Javé EE; Nuño-Lámbarri N
    Ann Hepatol; 2022; 27(2):100651. PubMed ID: 34896638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
    Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease.
    Xiao P; Liang P; Gao P; Wu J
    Front Endocrinol (Lausanne); 2022; 13():1057261. PubMed ID: 36531457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
    Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
    Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.